| Galectins in cancer: carcinogenesis, diagnosis and therapy AH Ebrahim, Z Alalawi, L Mirandola, R Rakhshanda, S Dahlbeck, ... Annals of translational medicine 2 (9), 2014 | 125 | 2014 |
| Expression of insulin‐like growth factor binding proteins in human breast cancer correlates with estrogen receptor status JA Figueroa, JG Jackson, WL McGuire, RF Krywicki, D Yee Journal of cellular biochemistry 52 (2), 196-205, 1993 | 108 | 1993 |
| Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with … RL Rocha, SG Hilsenbeck, JG Jackson, AV Lee, JA Figueroa, D Yee JNCI: Journal of the National Cancer Institute 88 (9), 601-606, 1996 | 106 | 1996 |
| Recombinant insulin‐like growth factor binding protein‐1 inhibits IGF‐I, serum, and estrogen‐dependent growth of MCF‐7 human breast cancer cells JA Figueroa, J Sharma, JG Jackson, MJ McDermott, SG Hilsenbeck, ... Journal of cellular physiology 157 (2), 229-236, 1993 | 106 | 1993 |
| Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer JA Figueroa, S DE RAAD, L TADLOCK, VO Speights, JJ RINEHART The Journal of urology 159 (4), 1379-1383, 1998 | 103 | 1998 |
| Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy JA Figueroa, A Reidy, L Mirandola, K Trotter, N Suvorava, A Figueroa, ... International reviews of immunology 34 (2), 154-187, 2015 | 102 | 2015 |
| Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer MW Saif, NA Podoltsev, MS Rubin, JA Figueroa, MY Lee, J Kwon, ... Cancer investigation 28 (2), 186-194, 2009 | 100 | 2009 |
| A Phase I/II study of LY900003, an antisense inhibitor of protein kinase C-α, in combination with cisplatin and gemcitabine in patients with advanced non–small cell lung cancer MA Villalona-Calero, P Ritch, JA Figueroa, GA Otterson, R Belt, E Dow, ... Clinical Cancer Research 10 (18), 6086-6093, 2004 | 100 | 2004 |
| Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding protein-1: evidence for an IGF-II autocrine growth loop JA Figueroa, AV Lee, JG Jackson, D Yee The Journal of Clinical Endocrinology & Metabolism 80 (12), 3476-3482, 1995 | 96 | 1995 |
| Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells D Yee, JG Jackson, TW Kozelsky, JA Figueroa Cell growth and differentiation 5, 73-73, 1994 | 79 | 1994 |
| The role of human papilloma virus (HPV) infection in non-anogenital cancer and the promise of immunotherapy: a review C Cobos, JA Figueroa, L Mirandola, M Colombo, G Summers, A Figueroa, ... International reviews of immunology 33 (5), 383-401, 2014 | 64 | 2014 |
| The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer JA Figueroa, D Yee Breast cancer research and treatment 22, 81-90, 1992 | 64 | 1992 |
| Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer L Mirandola, Y Yu, MJ Cannon, MR Jenkins, RL Rahman, DD Nguyen, ... Gynecologic oncology 135 (3), 573-579, 2014 | 57 | 2014 |
| Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues SE McGuire, SG Hilsenbeck, JA Figueroa, JG Jackson, D Yee Cancer letters 77 (1), 25-32, 1994 | 54 | 1994 |
| Mast cells and the liver aging process F Grizzi, G Di Caro, L Laghi, P Hermonat, P Mazzola, DD Nguyen, ... Immunity & Ageing 10, 1-10, 2013 | 52 | 2013 |
| Sex-driven differences in immunological responses: challenges and opportunities for the immunotherapies of the third millennium L Mirandola, R Wade, R Verma, C Pena, N Hosiriluck, JA Figueroa, ... International Reviews of Immunology 34 (2), 134-142, 2015 | 50 | 2015 |
| Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets L Mirandola, JA Figueroa, TT Phan, F Grizzi, M Kim, RL Rahman, ... Oncotarget 6 (5), 2812, 2015 | 50 | 2015 |
| Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data SP Kang, MW Saif JOP. J Pancreas (Online) 9 (2), 83-90, 2008 | 50* | 2008 |
| Prognostic indicators in early breast cancer JA Figueroa, D Yee, WL McGuire The American journal of the medical sciences 305 (3), 176-182, 1993 | 49 | 1993 |
| Addressing health disparities in Hispanic breast cancer: accurate and inexpensive sequencing of BRCA1 and BRCA2 M Dean, J Boland, M Yeager, KM Im, L Garland, M Rodriguez-Herrera, ... Gigascience 4 (1), s13742-015-0088-z, 2015 | 46 | 2015 |
Maurizio Chiriva InternatiAssociate Professor, University of Texas, Mdanderson Cancer CenterVerified email at mdanderson.org
